A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors

Antiviral Therapy

Volumn 8, Issue 6, 2003, Pages 595-602

  Kirk, Ole ^a   Lundgren, Jens D ^a   Pedersen, Court ^b   Mathiesen, Lars R ^a   Nielsen, Henrik ^c   Katzenstein, Terese L ^d   Obel, Niels ^e   Gerstoft, Jan ^d  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NELFINAVIR; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR;

EID: 0347594124     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial. Controlled Clinical Trials 2001; 22(2):160-175.
2. Smeaton LM, DeGruttola V, Robbins GK & Shafer RW. ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. Controlled Clinical Trials 2001; 22(2):142-159.
3. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2002; 288(2):222-235.
4. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2001; 2(4):276-313.
5. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H & Spreen W. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. Journal of the American Medical Association 2001; 285(9):1155-1163.
6. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine 1999; 341(25):1865-1873.
7. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S & Sun E. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine 2002; 346(26):2039-2046.
8. Kirk O, Katzenstein TL, Gerstoft J, Mathiesen L, Nielsen H, Pedersen C & Lundgren JD. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999; 13(1):F9-F16.
9. Katzenstein TL, Kirk O, Pedersen C, Lundgren JD, Nielsen H, Obel N, Nielsen C, Mathiesen LR & Gerstoft J. The Danish Protease Inhibitor Study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment ot human immunodeficiency virus Type 1 infection. Journal of Infectious Diseases 2000; 182(3):744-750.
10. Gerstoft J, Kirk O, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL & Lundgren JD. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003; 17:2045-2052.
11. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12(7):F51-F58.
12. Kirk O, Pedersen C, Law M, Gulick RM, Moyle G, Montaner J, Eron JJ Jr, Phillips AN & Lundgren JD. Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antiviral Therapy 2002; 7:271-281.
13. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M & Katzenstein DA. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. New England Journal of Medicine 2001; 345(6):398-407.
14. Jensen-Fangel S, Thomsen HF, Larsen L, Black FT & Obel N. The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. Journal of Acquired Immune Deficiency Syndromes 2001; 27(2):124-129.
15. van Praag RM, Wit FW, Jurriaans S, de Wolf F, Prins JM & Lange JM. Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. AIDS 2002; 16(5):719-725.
16. Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, Furrer H, Hirschel B & Perrin L. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 2000; 14(3):243-249.
17. Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R & Stevens M. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 2000; 14(11):1601-1610.
18. Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R & Stevens M. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000; 14(11):1591-1600.
19. Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S & Cooper DA. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombol study. AIDS 2000; 14(9):1171-1180.
20. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS 2000; 14(4):367-374.
21. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A & Gatell JM. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15(10):1261-1268.
22. Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J & Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clinical Trials 2003; 4(2):115-120.
23. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, Timpone J, Myers M, Basgoz N, Niu M & Hirsch MS. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Annals of Internal Medicine 1996; 124(12):1019-1030.
24. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA, Pradier C, Morfeldt L, Calvo G, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN & Lundgren JD for the D:A:D study. Cardiovascular risk factors in HIV patients - association with antiretroviral therapy results om the DAD Study. AIDS 2003; 17:1179-1193.
25. Roge BT, Katzenstein TL & Gerstoft J. Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. Scandinavian Journal of Infectious Diseases 2001; 33(4):306-311.
26. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z & Lundgren JD, for the MaxCminl trial group. A randomised trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in HIV-1 infected patients: the MaxCmin1 Trial. Journal of Infectious Diseases 2003; 188(5):635-642.